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I mmune-mediated encephalitis with autoantibodiesdirected against synaptic proteins has become animportant component of the differential diagnosis of
patients with encephalitis. Current estimates suggest
that a substantial proportion of patients once suspected to
have viral encephalitis in fact have an autoimmune etiology
for their symptoms.1 Additional autoantigen targets con-
tinue to be identified, and the phenotypic spectrum associ-
ated with autoimmune encephalitis continues to expand.
We describe a 3-year-old patient who presented with acute-
onset confusion, opsoclonus, chorea, and intractable sei-
zures. Neuroimaging disclosed involvement of the brain-
stem, basal ganglia, and hippocampi. γ-Aminobutyric acid
type B (GABAB) receptor autoantibodies were identified in
the serum and cerebrospinal fluid (CSF). Despite immuno-
modulating therapy, the patient died of overwhelming sep-
sis. To our knowledge, this is the first description of a pedi-
atric patient with GABAB receptor autoantibodies. The
presence of opsoclonus, ataxia, and chorea expands the
clinical phenotype and indicates that GABAB receptor auto-
immunity should be considered in cases of pediatric
encephalitis.
Report of a Case
Apreviously healthy 3-year-old boydeveloped confusion and
lethargy at homeduring the course of a single day, prompting
his parents to seekmedical attention. His initial examination
disclosed opsoclonus, dystonic movements of the tongue,
ataxia, and chorea affecting the limbs and trunk. Within 24
hours,hedeveloped frequentcomplexpartial seizuresandwas
intubated.His hyperkineticmovementswere controlledwith
midazolam sedation.
Initial CSF analysis demonstrated a lymphocytic pleocy-
tosis,withawhitebloodcell countof 154/μL (toconvert to×109
per liter,multiplyby0.001; 94% lymphocytes), a redbloodcell
count of 228 × 106/μL (to convert to ×1012 per liter,multiply by
1.0), a glucose level of 123mg/dL (to convert tomillimoles per
liter,multiplyby0.0555), andaprotein level of 59g/dL (to con-
vert to grams per liter, multiply by 10.0). Extensive evalua-
tion for infectious causes was unrevealing (including herpes
simplexvirus, varicella-zostervirus,humanherpesvirus6,Ep-
stein-Barr virus, cytomegalovirus, enterovirus, and myco-
plasma). A CSF paraneoplastic antibody panel, including an-
IMPORTANCE Autoantibodies to the γ-aminobutyric acid type B (GABAB) receptor have
recently been identified as a cause of autoimmune encephalitis. Most patients with GABAB
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been paraneoplastic in origin, with themajority of tumors representing small cell lung cancer.
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tineuronal nuclear antibody 1, Purkinje cell cytoplasmic
antibody 1, amphiphysin antibody, antineuronal nuclear an-
tibody 2, Purkinje cell cytoplasmic antibody type Tr, Purkinje
cell cytoplasmic antibody 2, antineuronal nuclear antibody 3,
collapsin response-mediator protein 5 IgG, anti-glial/
neuronal nuclear antibody 1, voltage-gated calcium channel
antibody, glutamic acid decarboxylase 65, and N-methyl-D-
aspartate receptorantibody,wasnegative.Neuroimagingdem-
onstratedmultifocal diffusion-weighted imaginghyperinten-
sities within the brainstem and cerebellum without
correspondingapparentdiffusioncoefficient restriction, lead-
ing to a working diagnosis of rhomboencephalitis (Figure 1).
Subsequent imaging showed evolution of these lesions to T2/
fluid-attenuated inversion recovery hyperintensity, with in-
volvement of the basal ganglia.
Electroencephalographydemonstrateddiffusedelta range
slowing and bioccipital spike-wave discharges with rapid
secondary generalization. The patient’s electrographic sei-
zures persisted despite administration of multiple anticon-
vulsants. Seizures were eventually controlled with a con-
tinuous infusion of pentobarbital sodium, but status
epilepticus recurred each time a wean was attempted. The
patient developed worsening cerebral edema, and a decom-
pressive posterior craniectomy was performed. At this time,
a cerebellar biopsy specimen was also obtained. This dem-
onstrated widespread astrogliosis and microglial activation
with Purkinje and granule cell loss (Figure 2). A CD3+ T-cell
infiltrate was also observed. Bacterial and viral culture of
biopsy tissue as well as 16S ribosomal RNA polymerase
chain reaction for bacteria, acid-fast bacilli, fungus, and
mold did not detect any pathogens.
The patient was treated with high-dose intravenous cor-
ticosteroids and intravenous immunoglobulin without clear
benefit. A search for an occult tumor was not performed. De-
spite intensive supportive care and aggressive seizure man-
agement, thepatientdevelopedoverwhelmingsepsis anddied
4weeks after his initial presentation. Theparents declined an
autopsy.
Two years after the patient’s initial presentation, testing
of archived serum and CSF identified diffuse reactivity to rat
neuropil with prominent reactivity in the cerebellum, thala-
mus, andhippocampus. Follow-up studiesusingHEK293 cells
transfectedwithGABAB1 andGABAB2were performed. Trans-
fected cells were fixed in 4% paraformaldehyde, permeabi-
lized with 0.1% Triton-X100, and incubated overnight at 4°C
with thepatient’sCSF (neat) andguineapigGABAB1 orGABAB2
polyclonal antibody. AlexaFluor secondary antibodies were
used forvisualization, andcolocalizationwasperformedusing
anImageJ-basedmacro.Thesestudies indicatedhigh-titeranti-
GABAB1 receptor autoantibodies.
Figure 1. Magnetic Resonance Imaging Findings
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Evidence of brainstem, cerebellar,
and basal ganglia involvement on
diffusion-weighted (A and D),
T1 contrast-enhanced (B), and
T2 fluid-attenuated inversion
recovery (C) images.
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Discussion
Autoimmune encephalitis associated with anti-GABAB auto-
antibodies is a recently described entity.2-4 Thus far, affected
patients have been adults with limbic encephalitis and sei-
zures, and about half of the cases have beenparaneoplastic in
origin, with small cell lung cancer being the most commonly
identifiedneoplasm.Toour knowledge, ourpatient is the first
pediatric patient described with this new form of autoim-
muneencephalitis. Ourpatient’s casewasnot associatedwith
an identified tumor (although an exhaustive search for an oc-
cult neoplasmwas not performed) or a recognized preceding
infection. In addition, althoughmesial temporal lobe involve-
mentwasdemonstrable on thepatient’s neuroimaging, hedid
not present with classic signs and symptoms of limbic
encephalitis (amnesia, psychosis, or agitation), although his
young age complicated assessment.
Severe, refractory seizures dominated the clinical course
in our patient, similar to previously described adult patients.
Although the patient’s seizures did not respond to immuno-
modulating treatments, it is not knownwhethermore aggres-
sive immunosuppressive therapy may have led to a treat-
ment response.5,6Theopsoclonus, chorea,and lingualdystonia
in our patient are novel phenotypic features (1 adult patient
presented with orobuccolingual dyskinesias without limb
involvement2). Such abnormal hyperkinetic movements are
consistentwith the role ofGABAB receptors inmodulatingdo-
paminergic neurotransmission7 and suggest that this entity
should be considered in the differential diagnosis of autoim-
munemovementdisorders8andperhapseven incasesofatypi-
cal opsoclonus-myoclonus-ataxia syndrome.
ARTICLE INFORMATION
Accepted for Publication: August 14, 2013.
Published Online:March 3, 2014.
doi:10.1001/jamaneurol.2013.4786.
Author Affiliations: Sanford Children’s Health
Research Center, Sanford Children’s Specialty Clinic,
Sioux Falls, South Dakota (Kruer); Institució
Catalana de Recerca i Estudis Avançats–Institut
d’Investigacions Biomèdiques August Pi i Sunyer
(ICREA-IDIBAPS), Department of Neurology,
Hospital Clinic, University of Barcelona, Barcelona,
Spain (Hoeftberger, Dalmau); Department of
Pediatric Neurology, Providence Brain and Spine
Institute, Portland, Oregon (Lim); Department of
Pediatric Neurology, Oregon Health & Science
University, Portland (Coryell, Svoboda);
Department of Neuropathology, Oregon Health &
Science University, Portland (Woltjer); Department
of Neurology, University of Pennsylvania,
Philadelphia (Dalmau).
Author Contributions:Dr Kruer had full access to
all of the data in the study and takes responsibility
for the integrity of the data and the accuracy of the
data analysis. Drs Kruer and Hoeftberger are joint
first authors.
Figure 2. Brain Biopsy Findings
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A and B, Biopsy demonstrates profound loss of cerebellar granule neurons and
Purkinje cells and prominent leptomeningeal inflammatory infiltrate
(hematoxylin-eosin, original magnification ×10 [A] and ×20 [B]). Gran indicates
granule cell layer; Lept, leptomeninges; Mol, molecular layer; and P, Purkinje cell
layer. C, Prominent CD3+ T cells are seen (3,3′-diaminobenzidine, original
magnification ×10). D, Occasional CD20+ B cells are evident (3,3′-
diaminobenzidine, original magnification ×20). E, Marked CD68+microglial
activation is present (3,3′-diaminobenzidine, original magnification ×20).
Research Case Report/Case Series γ-Aminobutyric Acid Type B Receptor Autoimmunity
622 JAMANeurology May 2014 Volume 71, Number 5 jamaneurology.com
Downloaded From:  by a Universidad de Barcelona User  on 02/07/2018
Copyright 2014 American Medical Association. All rights reserved.
Study concept and design: Kruer.
Acquisition of data: All authors.
Analysis and interpretation of data: Kruer, Dalmau.
Drafting of the manuscript: Kruer.
Critical revision of the manuscript for important
intellectual content: All authors.
Obtained funding:Woltjer, Dalmau.
Administrative, technical, andmaterial support:
Hoeftberger, Svoboda, Woltjer, Dalmau.
Conflict of Interest Disclosures:Dr Dalmau serves
on the editorial board ofNeurology; has a patent
issued for theMa2 autoantibody test (US
6,387,639; issuedMay 14, 2002); has a patent for
the N-methyl-D-aspartate receptor autoantibody
test (US 7,972,796 B2; issued July 5, 2011); has filed
for patents for the GABAB receptor and LGI1
(leucine-rich, glioma inactivated 1) autoantibody
tests; receives license fee payments for the
N-methyl-D-aspartate receptor autoantibody test
from Euroimmun; receives royalties from the
patentedMa2 autoantibody test and the patented
N-methyl-D-aspartate receptor autoantibody test;
and has a patent application pending for the use of
GABAB receptor and LGI1 as an autoantibody test.
No other disclosures were reported.
Funding/Support:Dr Kruer is supported by grant
K08NS083739 from the National Institute of
Neurological Disorders and Stroke, the Sanford
Health Foundation, the Sanford-Mayo Collaborative
Fund, the Dystonia Medical Research Foundation,
the Child Neurology Society, and the American
Academy of Cerebral Palsy and Developmental
Medicine. DrWoltjer is supported by grant P30
AG008017 23 from the National Institute on Aging.
Dr Dalmau is supported by Euroimmun, grants
R01CA107192 and R01CA89054-06A2 from the
National Institutes of Health, and theMcKnight
Foundation.
Role of the Sponsor: The funding organizations
had no role in the design and conduct of the study;
collection, management, analysis, and
interpretation of the data; preparation, review, or
approval of themanuscript; and decision to submit
themanuscript for publication.
REFERENCES
1. Gable MS, Sheriff H, Dalmau J, Tilley DH, Glaser
CA. The frequency of autoimmune
N-methyl-D-aspartate receptor encephalitis
surpasses that of individual viral etiologies in young
individuals enrolled in the California Encephalitis
Project. Clin Infect Dis. 2012;54(7):899-904.
2. Lancaster E, Lai M, Peng X, et al. Antibodies to
the GABA(B) receptor in limbic encephalitis with
seizures: case series and characterisation of the
antigen. Lancet Neurol. 2010;9(1):67-76.
3. Boronat A, Sabater L, Saiz A, Dalmau J, Graus F.
GABA(B) receptor antibodies in limbic encephalitis
and anti-GAD-associated neurologic disorders.
Neurology. 2011;76(9):795-800.
4. Frisullo G, Della Marca G, Mirabella M, et al. A
human anti-neuronal autoantibody against GABA B
receptor induces experimental autoimmune
agrypnia. Exp Neurol. 2007;204(2):808-818.
5. Kruer MC, Koch TK, Bourdette DN, et al. NMDA
receptor encephalitis mimicking seronegative
neuromyelitis optica.Neurology. 2010;74(18):1473-
1475.
6. Titulaer MJ, McCracken L, Gabilondo I, et al.
Treatment and prognostic factors for long-term
outcome in patients with anti-NMDA receptor
encephalitis: an observational cohort study. Lancet
Neurol. 2013;12(2):157-165.
7. Vacher CM, GassmannM, Desrayaud S, et al.
Hyperdopaminergia and altered locomotor activity
in GABAB1-deficient mice. J Neurochem.
2006;97(4):979-991.
8. Panzer J, Dalmau J. Movement disorders in
paraneoplastic and autoimmune disease. Curr Opin
Neurol. 2011;24(4):346-353.
γ-Aminobutyric Acid Type B Receptor Autoimmunity Case Report/Case Series Research
jamaneurology.com JAMANeurology May 2014 Volume 71, Number 5 623
Downloaded From:  by a Universidad de Barcelona User  on 02/07/2018
